Monopar Therapeutics Inc (MNPR)

06:32 AM

Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks

06:32 AM

06:07 AM

Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus

06:07 AM

03:33 AM

Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World

03:33 AM

03:11 AM

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus

03:11 AM

02:42 AM

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times

02:42 AM

May 02, 2025

Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World

May 02, 2025

Apr 30, 2025

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Yahoo Finance

Apr 30, 2025

Apr 29, 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times

Apr 29, 2025

Apr 29, 2025

Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey

Apr 29, 2025

Apr 25, 2025

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Apr 25, 2025

Apr 22, 2025

(MNPR) Investment Analysis - news.stocktradersdaily.com

Apr 22, 2025

Apr 10, 2025

Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com

Apr 10, 2025

Apr 06, 2025

(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks

Apr 04, 2025

Apr 04, 2025

Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 04, 2025

HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World

Apr 04, 2025

Apr 04, 2025

Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Apr 04, 2025

Apr 03, 2025

What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World

Apr 03, 2025

Apr 02, 2025

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

Apr 02, 2025

Apr 02, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo

Apr 02, 2025

Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025

Apr 01, 2025

Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq

Apr 01, 2025

Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025

Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025

Apr 01, 2025

Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks

Apr 01, 2025

Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz

Mar 31, 2025

Mar 31, 2025

Monopar Therapeutics SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan

Mar 31, 2025

Mar 28, 2025

MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView

Mar 28, 2025

Mar 21, 2025

Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance

Mar 21, 2025

Mar 21, 2025

Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Mar 21, 2025

Mar 20, 2025

Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 19, 2025

Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha

Mar 19, 2025

Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com

Mar 19, 2025

Mar 19, 2025

Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks

Mar 19, 2025

Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK

Mar 19, 2025

Mar 16, 2025

(MNPR) Trading Report - news.stocktradersdaily.com

Mar 16, 2025

Mar 08, 2025

Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St

Mar 08, 2025

Mar 04, 2025

Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha

Mar 04, 2025

Mar 03, 2025

Monopar Therapeutics appoints new CFO - Investing.com

Mar 03, 2025

Mar 03, 2025

Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks

Mar 03, 2025

Mar 03, 2025

Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com

Mar 03, 2025

Mar 03, 2025

Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia

Mar 03, 2025

Feb 24, 2025

Monopar Therapeutics appoints new board member - Investing.com

Feb 24, 2025

Feb 24, 2025

Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK

Feb 24, 2025

Feb 24, 2025

Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks

Feb 24, 2025

Feb 23, 2025

Trend Tracker for (MNPR) - Stock Traders Daily

Feb 23, 2025

Feb 19, 2025

Copper wired: Monopar to electrify Wilson disease? - BioWorld Online

Feb 19, 2025